I migliori medici di Intervento su raccomandazione medica - TOP-32medici

Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.

He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.

He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.

Education and Specialization

• 2006 – Ankara University, Faculty of Medicine
• 2007, 2011 – Baskent University, Faculty of Medicine, Residency Training

Experience

• 2011, 2013 – Konya Çumra State Hospital – Radiology Specialist
• 2013, 2018 – Baskent University Konya Application and Research Center, Interventional Radiology Unit – Lecturer
• 2018,2019 – Baskent University Konya Application and Research Center, Interventional Radiology Department – Associate Professor
• 2019  Present – Medical Park Antalya Hospital Complex, Interventional Radiology Department – Associate Professor

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Dr. Alon Friedlander, MD, is an orthopedic surgeon and a spine and scoliosis specialist for adults and children. He is the Director of the Orthopedic Department at Sheba Medical Center. He is also an Associate Professor of Orthopedics at Tel Aviv University. He is listed by Forbes among Israel’s Top Doctors.

He treats complex spine disorders with minimally invasive and open surgery. His procedures include anterior and posterior fixation. His focus areas are scoliosis and other deformities, tumors, stenosis and instability, and disc herniation. Education: MD, Tel Aviv University; residency, Sheba Medical Center. Fellowships: Institut Mutualiste Montsouris and University Hospitals of Strasbourg (France); Queen Mary Hospital and the Duchess of Kent Children’s Hospital (Hong Kong).

Advisory roles: IDF referral physician. Consultant to soccer teams. Specialist for the Spartak Basketball Club (knee injuries).

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Доктор Онур Шахин окончил стоматологический факультет Университета Хаджеттепе в 2011 году и завершил специализированную подготовку на кафедре челюстно-лицевой хирургии Университета Гази в 2016 году. С 2017 года он работает академиком на кафедре челюстно-лицевой хирургии Измирского университета Катип Челеби. В 2021 году ему было присвоено звание доцента. Кроме того, с 2017 года он продолжил обучение в докторантуре на медицинском факультете Университета Эге, на кафедре стволовых клеток. Интересы доктора Онура Шахина включают в себя передовую имплантологию, аугментацию твердых и мягких тканей атрофированных челюстей, лечение all-on-X, скуловые, крыловидные и трансназальные имплантаты, медикаментозный остеонекроз челюсти (MRONJ), а также стволовые клетки и регенеративную терапию. Он был приглашенным докладчиком на многих национальных и международных симпозиумах по имплантологии и челюстно-лицевой хирургии и провел множество практических и кадаверных курсов по имплантологии. Доктор Шахин, который выполнил первый случай с имплантатами скуловой кости, крыловидной кости и трансназальной имплантации в Турции, имеет более 100 пациентов, прошедших лечение с помощью этих имплантатов. Он опубликовал более 50 статей в национальных и международных журналах и более 100 постеров/устных докладов, представленных на национальных и международных конгрессах, связанных с его научной областью. Также на сегодняшний день было сделано более 300 ссылок на публикации доктора Шахина.

He entered Istanbul University Cerrahpaşa Faculty of Medicine in 1987 and started his compulsory service in Akçaabat district of Trabzon in 1993. In January 1995, he was admitted to the Hepato-Biliary Surgery service of the Universite Libre Bruxelles Erasmus Hospital in Brussels, Belgium. He started his General Surgery residency in October 1996 and became a General Surgery Specialist in Belgium in 2002 with the thesis "Le Re-do Gastroplastie dans le traitement des complications des Procedure Bariatriques pour Obesité Morbide" (Revision Surgery in the Treatment of Complications of Bariatric Procedures for Morbid Obesity).

He worked in the Hepatobiliary Surgery service of ULB Erasmus Hospital until October 2003, and then in October 2003 he joined Providence Hospital in Neuchatel, Switzerland as Deputy Chief of Surgery Clinic. In March 2004, he was appointed as Chief of Surgery Clinic at Neuchatel Hospital Cadolles Pourtales NHP and played an important role in Advanced Laparoscopic Surgery, Bariatric Surgery, Oncologic Surgery, Traumatology, Vascular and Thoracic Surgery and resident training.

He started his career in the private sector by obtaining equivalency in the field of General Surgery at Çukurova University. He is currently serving as a General Surgery Specialist at NPISTANBUL Hospital.

Areas of Interest:

• Obesity and Metabolic Surgery
• Laparoscopic Surgery
• Breast Surgery
• Proctology
• Goiter/Thyroid Surgery
• Colon and Cancer Surgery

YOSAPHON VICHIENVANITCHKUL, M.D.

General Internal Medicine

Graduated (M.D. From)

Doctor of Medicine, Faculty of Medicine, Srinakharinwirot University

Working in general internal medicine treat patients with a wide range of acute and long-term medical conditions.

Certificates

Certificate of Internal Medicine, Faculty of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force

Current Positions

General Internal Medicine doctor at Intrarat Hospital

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education and Specialization

• Hacettepe University Faculty of Medicine – English Medical Education
• Akdeniz University Faculty of Medicine – Internal Medicine – Residency
• Akdeniz University Hospital – Nephrology – Subspecialty Training
• San Bortolo Hospital, Vicenza, Italy – Critical Care Nephrology and Transplantation – Fellowship
• Hacettepe University Faculty of Medicine – Associate Professorship

Professional Memberships

1. Turkish Society of Nephrology (TND)
2. European Society of Nephrology (ERA-EDTA)
3. Middle East Society of Organ Transplantation (MESOT)
4. International Society of Nephrology (ISN)

Education and Specialization

1998 - Undergraduate (Medicine): Istanbul University Faculty of Medicine

2004 - Master’s Degree: Istanbul University Faculty of Medicine

2005 - 2011 - PhD (Urology): Taksim Training and Research Hospital

2020 - Associate Professor: Yeni Yüzyıl University

Experience

2011 to 2013 - Urology Specialist: Kastamonu Dr. Münif Islamoğlu State Hospital

2013 to 2014 - Urology Specialist: Izmir Private Marine Hospital

2014 to 2014 - Urology Specialist: Istanbul Murat Kölük State Hospital

2014 to 2016 - Urology Specialist: Gaziosmanpaşa Taksim Training and Research Hospital

2016 to 2020 - Faculty Member: Yeni Yüzyıl University Gaziosmanpaşa Hospital

2020 - Associate Professor: Yeni Yüzyıl University Gaziosmanpaşa Hospital

Articles Published in International Refereed Journals: A1

1)NUHOĞLU BARIŞ, BALCI MUSTAFA BAHADIR CAN, AYDIN MEMDUH, HAZAR İSMET, ONUK ÖZKAN, TAŞ TUNCAY, FİKRİ ONUR (2011). The Role of Bipolar Transurethral Vaporization in the Management of Benign Prostatic Hyperplasia. Urologia Internationalis.

2)BALCI MUSTAFA BAHADIR CAN, TAŞ TUNCAY, HAZAR İSMET, AYDIN MEMDUH, ONUK ÖZKAN, ÇAKIROĞLU BASRİ, INTELLECTUAL HONOR, ÖZKAN ARİF, NUHOĞLU BARIŞ (2014). Applicability and Effectiveness of Virtual Reality Simulator Training in Urologic Surgery: A Double-Blind Randomized Study. NOBEL MEDIUS.

3)ONUK ÖZKAN, TAŞ TUNCAY, ŞENTÜRK AB, ORHUN SINANOĞLU, BALCI MUSTAFA BAHADIR CAN, ÇELİK O, NUHOĞLU BARIŞ (2014). Right-Sided Bochdalek Hernia with Intrathoracic Ectopic Kidney in an Advanced-Age Adult: A Case Report. Urologia Internationalis.

4)ONUK ÖZKAN, BALCI MUSTAFA BAHADIR CAN, HAZAR İSMET, TAŞ TUNCAY, ÖZKAN ARİF, NUHOĞLU BARIŞ (2015). Giant Bladder Stone in a Young Woman. Journal of Academic Research in Medicine.

5)DİNÇER MUHAMMET MURAT, ONUK ÖZKAN (2015). Phalloplasty and Penile Prosthesis Implantation for Micropenis. Journal of Academic Research in Medicine

6)ONUK ÖZKAN, ARSLAN BURAK, HAZAR İSMET, ÖZKAN ARİF, ÇİLESİZ NUSRET CAN, NUHOĞLU BARIŞ (2016). Clinical Course of a Case with Sarcomatoid Renal Cell Carcinoma. International Journal of Medical and Pharmaceutical Research.

7)BALCI MUSTAFA BAHADIR CAN, ONUK ÖZKAN, HAZAR İSMET, ÖZKAN ARİF, ÇİLESİZ NUSRET CAN, ARSLAN BURAK, NUHOĞLU BARIŞ (2016). Incidental Prostate Cancer Frequency and Features of Patients Undergoing Radical Cystoprostatectomy. Journal of Academic Research in Medicine.

8)HİRİK ERKAN, BOZKURT ALİSEYDİ, KARABAKAN MEHMET, ONUK ÖZKAN, BALCI MUSTAFA BAHADIR CAN, AYDIN MEMDUH, ÇAKAN MURAT, NUHOĞLU BARIŞ (2016). Results of Tadalafil Treatment in Patients Following an Open Nerve-Sparing Radical Prostatectomy. Archivio Italiano di Urologia e Andrologia.

9)ARSLAN BURAK, AKBULUT MEHMET, ONUK ÖZKAN, HAZAR İSMET, ÖZKAN ARİF, GEZMİŞ CEM TUĞRUL, ÇETİN BUĞRA, AYDIN MEMDUH (2016). Risk Factors Affecting the Outcomes of Docetaxel-Prednisone Combination in the Treatment of Metastatic Castration-Resistant Prostate Cancer. British Journal of Medicine and Medical Research.

10)ONUK ÖZKAN, ARSLAN BURAK, YANARAL FATİH, HAZAR İSMET, ÖZKAN ARİF, GEZMİŞ TUĞRUL, NUHOĞLU BARIŞ (2016). Management of Gunshot Injury of Glans Penis that Extends to Anterior Urethra: A Rare Case Report. Haseki Medical Bulletin.

11)ARSLAN BURAK, AKBULUT MEHMET FATİH, ONUK ÖZKAN, KÜÇÜKTOPCU ONUR, ÇİLESİZ NUSRET CAN, ÖZKAN ARİF, YAZICI GÖKHAN (2017). A Comparison of Amplatz Dilators and Metal Dilators for Tract Dilatation in Mini-Minute Nephrolithotomy. International Urology and Nephrology.

12)ARSLAN BURAK, ONUK ÖZKAN, EROĞLU ALİ, GEZMİŞ TUĞRUL, AYDIN MEMDUH (2017). Female Sexual Function Follows a Novel Transobturator Sling Procedure without Paraurethral Dissection (Modified-TOT). International Braz J Urol.

13)ARSLAN BURAK, ONUK ÖZKAN, HAZAR İSMET, AYDIN MUAMMER, ÇİLESİZ NUSRET CAN, EROĞLU ALİ, NUHOĞLU BARIŞ (2017). Prognostic Value of Endocan in Prostate Cancer: Clinicopathologic Association Between Serum Endocan Levels and Biochemical Recurrence after Radical Prostatectomy. Tumori Journal.

14)ONUK ÖZKAN, ÇİSELİS NUSRET CAN, HAZAR İSMET, GÖZMÜŞ TUĞRUL, ÖZCANLI YUSUF TURUSHAN, DİNÇER MUHAMMET MURAT, NUHOĞLU BARIŞ (2016). Treatment of Giant Ureteral Fibroepithelial Polyp: A Case Report Using an Endoscopic Approach. Journal of Academic Research in Medicine.

15)YANARAL FATİH, BALCI MUSTAFA BAHADIR CAN, OZGÖR FARUK, ŞİMŞEK ABDULMUTALİP, ONUK ÖZKAN, AYDIN MUAMMER, NUHOĞLU BARIŞ (2017). Comparison of Conventional Dressings and Vacuum-Assisted Closure in the Wound Therapy of Fournier's Gangrene. Archivio Italiano di Urologia e Andrologia.

16)ONUK ÖZKAN (2018). A Minimally Invasive Modified Technique for Female Stress Urinary Incontinence: Transobturator Tape without Paraurethral Dissection. Videosurgery and Other Miniinvasive Techniques.

17)HAZAR İSMET, ONUK ÖZKAN, ÖZKAN ARİF, KIR GÜLAY, ÇİLESİZ NUSRET CAN, BALCI MUSTAFA BAHADIR CAN, NUHOĞLU BARIŞ (2018). Treatment of Primary Vesicovaginal Fistula Repair with Bladder Mucosal Flap: A Report of Initial Case Series. Journal of Academic Research in Medicine.

18)ONUK ÖZKAN, ARSLAN BURAK, GEZMİŞ TUĞRUL, ÇETİN BUĞRA, GÖV TAHA, YAZICI GÖKHAN, GÜRKAN OKAN, ÖZDEMİR ENVER (2018). Is the Plasma Endocan Level a Reliable Predictor for the Severity of Erectile Dysfunction?. International Urology and Nephrology.

19)ÖZKAN ARİF, ÇİLESİZ NUSRET CAN, KALKANLI ARİF, GÜNSEVEN KADIR ÖMÜR, ONUK ÖZKAN, HAZAR İSMET, BALCI MUSTAFA BAHADIR CAN (2018). Comparison of Local Anesthetic Efficacy of Lidocaine Gel and Lidocaine Gel-Intramuscular Diclofenac Combination in Patients Undergoing Flexible Cystoscopy. Journal of Academic Research in Medicine.

20)ARSLAN BURAK, GÖNÜLTAŞ SERKAN, GÖKMEN ERSİN, ÖZMAN OKTAY, ONUK ÖZKAN, YAZICI GÖKHAN, GÖV TAHA, ÖZDEMİR ENVER (2019). Does YouTube Include High-Quality Resources for Training on Laparoscopic and Robotic Radical Prostatectomy?. World Journal of Urology.

21)ONUK ÖZKAN, NUHOĞLU BARIŞ, ÖZKAN ARİF, TAŞ TUNCAY, ÇİLESİZ NUSRET CAN, HAZAR İSMET, BALCI MUSTAFA BAHADIR CAN (2019). Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma. Journal of Academic Research in Medicine.

22)ONUK ÖZKAN, ÖZKAN ARİF, ÇİLESİZ NUSRET CAN, KALKANLI ARİF (2019). Vacuum-Assisted Treatment in Fournier Gangrene. Journal of Academic Research in Medicine.

23)LOVMIS M, ONUK ÖZKAN, AKTAŞ S, ALKARA U, MERCİLESS O, LOVMIS S (2020). Two Renal Transplants From Living Donors With Horseshoe Kidneys. Urology.

24)ALİ EROĞLU, MUAMMER AYDIN, ÖZKAN ONUK, NUSRET CAN ÇİLESİZ, BARIŞ NUHOĞLU (2020). Investigation of Sexual Dysfunction in Premenopausal Women with Urinary Incontinence. Journal of Academic Research in Medicine.

25)TUNCAY TAŞ, BASRİ ÇAKIROĞLU, ERSAN ARDA, ÖZKAN ONUK, BARIŞ NUHOĞLU (2021). Early Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunction. Sexual Medicine,.

26)ÖZKAN ONUK, NUSRET CAN ÇİLESİZ, ARİF ÖZKAN, ELBRUS ZARBALİYEV, NURTEN DAYIOĞLU, BARIŞ NUHOĞLU (2020). Urological Injuries in the Civil War of Libya.

Publications and articals goes on.

• AREAS OF INTEREST
• Spine surgery
• Scoliosis
• Kyphosis
• Childhood spinal diseases
• Degenerative spine diseases
• Lumbar cervical disc herniation
• Knee hip joint disorders
• Orthopedic trauma surgery

• Education and Specialization
• 2010 - Cerrahpasa Faculty of Medicine - Medical Education
• 2016 - Medeniyet University Goztepe Training and Research Hospital - Specialization

• Experience
• 2016 - 2022 - Sisli Hamidiye Etfal Training and Research Hospital
• 2015 -2016 - Chicago Loyola University, Illinois, USA

• Courses and Certificates
• 13.12.2019-14.12.2019 Turkish Spine Society Eurospine Accredited Education Modules
• 08.11.2019-10.11.2019 Turkish Spine Society Eurospine Accredited Education Modules
• 31.08.2015-04.09.2015 Basic Microsurgery Course, MICROSURGERY EDUCATION-RESEARCH LABORATORY
• AO Trauma Course-Basic Principles of Fracture Management
• 07.06.2014-10.06.2014 Fracture Management, Kodi Kojima Chairperson AOTrauma Education Commission
• 01.03.2013-02.03.2013 Instrumentation in Arthroscopic Surgery

• Professional Memberships
• Turkish Orthopedics and Traumatology Association (TOTBİD)
• Turkish Medical Association - Istanbul Medical Chamber

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

uzmanlık

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. David (Dudi) Mishali, MD, is Director of Pediatric and Congenital Cardiothoracic Surgery at Sheba Medical Center. He treats infants and children with congenital heart defects. His work includes rare, high-risk anomalies and complex newborn reconstructions.

He trained internationally. He completed his residency at Rabin Medical Center and clinical fellowships in cardiac surgery at the Cleveland Clinic and in congenital pediatric cardiothoracic surgery at UCSF. He is board certified in cardiothoracic surgery. He developed and implemented minimally invasive methods that reduce surgical trauma and improve cosmetic results.

He is a Senior Lecturer at Tel Aviv University’s Sackler Faculty of Medicine. He has written many peer-reviewed papers and book chapters, including on point-of-care testing in children during cardiopulmonary bypass and on accessory mitral valve tissue. He holds a leadership role at a hospital ranked among the world’s top 10.